Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01042925
First received: January 4, 2010
Last updated: January 14, 2013
Last verified: January 2013

January 4, 2010
January 14, 2013
January 2010
December 2012   (final data collection date for primary outcome measure)
  • Safety and tolerability of XL147 in combination with trastuzumab and in combination with trastuzumab and paclitaxel [ Time Frame: safety assessments at weekly study visits ] [ Designated as safety issue: Yes ]
  • In Phase 1, the maximum tolerated dose (MTD) of XL147 when administered in combination with trastuzumab and in combination with trastuzumab and paclitaxel [ Time Frame: assessed by weekly study visits ] [ Designated as safety issue: Yes ]
  • In Phase 2, objective tumor response [ Time Frame: every 6 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01042925 on ClinicalTrials.gov Archive Site
  • Duration of response and progression-free survival (Phase 2) [ Time Frame: every 6 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics and pharmacodynamics of XL147 and trastuzumab when given in combination, and of XL147, trastuzumab, and paclitaxel when given in combination [ Time Frame: assessed weekly, then every 3 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen

Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with trastuzumab (Herceptin) and in combination with trastuzumab and paclitaxel. After the MTD is established for each combination (Phase 2), subjects will be enrolled to evaluate the preliminary efficacy and safety of these combinations in metastatic HER2 positive breast cancer. Both trastuzumab and paclitaxel are used in the treatment of metastatic breast cancer (MBC), but patients can develop resistance.

The link between PI3K mutations and trastuzumab resistance has been seen in breast cancer patients. This suggests that inhibitors of the PI3K/PTEN pathway may have the potential to restore sensitivity to trastuzumab. Similarly, introduction of activated mutant forms of PI3K has been shown to transform and confer paclitaxel resistance to immortalized breast epithelial cells. XL147 is a potent and selective inhibitor of PI3K and inhibits phosphorylation of multiple downstream components of PI3K/PTEN signaling. Therefore, XL147 may have utility in the treatment of trastuzumab resistant/refractory and HER2-positive MBC when administered in combination with trastuzumab alone or with trastuzumab and paclitaxel.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Breast Cancer
  • Breast Neoplasms
  • Drug: XL147 (SAR245408)
    administered orally once daily as tablet(s)
  • Biological: trastuzumab
    administered by IV once every 3 weeks
    Other Name: Herceptin
  • Drug: paclitaxel
    administered by IV once every week
  • Experimental: Arm 1
    XL147 in combination with trastuzumab
    Interventions:
    • Drug: XL147 (SAR245408)
    • Biological: trastuzumab
  • Experimental: Arm 2
    XL147 in combination with trastuzumab and paclitaxel
    Interventions:
    • Drug: XL147 (SAR245408)
    • Biological: trastuzumab
    • Drug: paclitaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
42
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject has pathologically and radiologically confirmed metastatic HER2 positive breast cancer (Stage IV disease). Subjects must have received and progressed on at least one prior trastuzumab-containing regimen for metastatic disease. For subjects in Arm 2, they must also have received at least one prior taxane-containing regimen.
  • The subject has at least one lesion that is not within a previously radiated field and measurable on computerized tomography (CT) or magnetic resonance imaging scan (MRI)
  • The subjects enrolled in Phase 2 must be willing to undergo a biopsy of the primary tumor or a tumor metastasis at baseline, if tumor tissue is amenable to biopsy
  • The subject's primary tumor and/or metastatic lesion must overexpress HER2
  • For subjects enrolled in Phase 2: samples from archival or fresh tissue, or a tissue block of the subject's tumor.
  • The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • The subject has adequate organ and marrow function
  • The subject is capable of understanding the informed consent and complying with the protocol and has signed the informed consent document prior to any study-specific screening procedures or evaluations being performed.
  • Sexually active subjects must agree to use a medically-accepted barrier method of contraception during the course of the study and for 3 months following discontinuation of study treatments. For subjects using oral contraceptives, a barrier method must be used in addition to the oral contraceptive
  • Subjects of childbearing potential must have a negative pregnancy test at screening and enrollment

Exclusion Criteria:

  • The subject has previously been treated with a selective inhibitor of PI3K and / or AKT
  • Certain restrictions on prior therapies apply
  • The subject has not recovered from toxicity due to prior therapy to Grade ≤ 1 or to pre-therapy baseline
  • The subject has untreated, symptomatic, or progressive brain metastases. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for ≥4 weeks prior to first study treatment
  • The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial thromboplastin time (PTT) test results at screening that are ≥ 1.3 times above the laboratory upper limit of normal
  • The subject has a diagnosis of uncontrolled diabetes mellitus
  • The subject has uncontrolled significant intercurrent illness
  • The subject has uncontrolled hypertension or other clinically significant cardiovascular disease
  • The subject has left ventricular ejection fraction (LVEF) ≤ 50%
  • The subject has a baseline corrected QT interval ≥ 460 ms
  • The subject is currently receiving anticoagulation with therapeutic doses of warfarin (low-dose warfarin ≤ 1mg/day is permitted)
  • The subject is pregnant or breastfeeding
  • The subject is known to be positive for the human immunodeficiency virus (HIV) (a test for HIV at screening is not required)
  • The subject has any other diagnosis of malignancy or evidence of malignancy (except non-melanoma skin cancer, in situ carcinoma of the cervix) within 2 years prior to screening for this study
  • The subject has a previously identified allergy or hypersensitivity or is intolerant to components of any of the study treatment formulations
  • The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Spain
 
NCT01042925
ARD11439, XL147-203
Yes
Sanofi
Sanofi
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP